Milestone Pharmaceuticals

Company snapshot

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a patient-centric commercial-stage biopharmaceutical company dedicated to bringing innovative cardiology products to market. Our lead product, CARDAMYST™ (etripamil), is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. We are also dedicated to the continued cli

• 5 approved product(s) across US/EU regulatory metadata.
• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Milestone Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Milestone Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Etripamil Nasal Spray 70mg — Phase 1

2. Jun 5, 2026 Clinical update

   Placebo — Phase 3

3. May 23, 2026 Clinical update

   Etripamil — Phase 3

4. May 23, 2026 Clinical update

   Etripamil NS — Phase 3

5. May 23, 2026 Clinical update

   Etripamil NS 70 mg — Phase 3

View all clinical trial activity →

• What is Milestone Pharmaceuticals?

  Milestone Pharmaceuticals is a pharma organization headquartered in Montreal, CA. It trades on NYSE under ticker MIST. Primary therapeutic focus areas include Paroxysmal Supraventricular Tachycardia, Atrial Fibrillation, Tachycardia, Supraventricular, Paroxysmal Supraventricular

• Is Milestone Pharmaceuticals publicly traded?

  Yes. Milestone Pharmaceuticals is listed with ticker MIST on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Milestone Pharmaceuticals develop or market?

  We link 6 drug profile(s) where Milestone Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/milestone-pharmaceuticals#company-drugs.

• What are the latest developments for Milestone Pharmaceuticals?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Milestone Pharmaceuticals focus on?

  Milestone Pharmaceuticals focuses on Paroxysmal Supraventricular Tachycardia, Atrial Fibrillation, Tachycardia, Supraventricular based on our analysis of their pipeline programs and drug development activities.